Cadonilimab as Neoadjuvant Therapy in Resectable Stage II-III MSI-H/dMMR Colorectal Cancer

NCT05913570 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

22

Enrollment

OTHER_GOV

Sponsor class

Conditions

Colorectal Cancer
Mismatch Repair-deficient (dMMR)
Microsatellite Instability-high (MSI-H)
Neoadjuvant Therapy

Interventions

DRUG: Cadonilimab (®), a PD-1/CTLA-4 bi-specific antibody

Sponsor

LiuYing